The goals of the San Diego Biomedical Research Institute (SDBRI) are to: Identify individuals who are at risk of either developing a disease or progressing to a new disease stage so that they can be selected for therapy. Identify which at risk individuals will be responsive to specific therapies and which will not. And to determine why some at risk individuals are not good candidates for specific therapies and develop interventions that increase sensitivity to treatment.The SDBRI have recently identified a combination of markers in the blood of children newly diagnosed with type 1 diabetes that will predict whether the patient will require a low or a high dose of insulin to maintain normal blood glucose levels. The work is published in the journal Clinical Immunology. The clinical relevance is that patients who have a blood glucose that is easier to control might be more responsive to immunotherapy to reverse disease.One of their new programs is focused on identifying molecules in the blood that are responsible for making patients who are obese more susceptible to cancer.